HK Stock Market Move | XTALPI (02228) high open more than 6%, reaching a platform strategic cooperation of 345 million US dollars with Lilly on AI-empowered bispecific antibodies.

XTALPI (02228) opened more than 6% higher, rising 6.05% to HK$11.4 as of the time of writing, with a trading volume of HK$41.9461 million. On the news front, Crystal Pi Technology announced that its wholly-owned subsidiary Ailux has reached a strategic cooperation and platform authorization agreement with Lilly, with a total value of up to $345 million. This includes tens of millions of dollars in upfront payments and recent milestone payments. Lilly will leverage Ailux's proprietary platform to accelerate the discovery and development of bispecific antibodies (bispecifics) in multiple therapeutic areas, as well as utilize its AI antibody development platform to accelerate internal pipeline research. This marks another collaboration between Crystal Pi Technology and Lilly following their $250 million AI small molecule drug collaboration in 2023. It is reported that Ailux has been a key focus of Crystal Pi Technology's large molecule drug development platform since 2021, and has experienced rapid growth and commercialization in the past two years. Ailux, with its integrated dry and wet research and development model, achieves precise AI antibody drug design and engineering, effectively addressing the challenges of high cost and long cycles in drug discovery, helping pharmaceutical companies explore richer targeting mechanisms and differentiated drug development pathways. In the future, Ailux will also have the ability to advance a variety of next-generation AI-designed antibody drugs to later stages of clinical trials to gain more impactful major commercial collaborations.